Maze Therapeutics, Inc. $MAZE Shares Sold by Foresite Capital Management IV LLC

Foresite Capital Management IV LLC lessened its stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) by 75.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 522,657 shares of the company’s stock after selling 1,589,262 shares during the quarter. Maze Therapeutics comprises approximately 7.4% of Foresite Capital Management IV LLC’s holdings, making the stock its 3rd largest position. Foresite Capital Management IV LLC’s holdings in Maze Therapeutics were worth $13,552,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Maze Therapeutics in the 1st quarter valued at approximately $57,000. Goldman Sachs Group Inc. bought a new stake in Maze Therapeutics during the first quarter worth approximately $145,000. Rhumbline Advisers bought a new stake in Maze Therapeutics during the first quarter worth approximately $80,000. Geode Capital Management LLC grew its holdings in Maze Therapeutics by 8.8% during the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after purchasing an additional 18,773 shares during the last quarter. Finally, Ensign Peak Advisors Inc acquired a new position in Maze Therapeutics during the second quarter valued at approximately $227,000.

Maze Therapeutics Trading Down 3.1%

Shares of MAZE stock opened at $50.21 on Monday. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $52.86. The firm’s fifty day simple moving average is $44.82 and its 200 day simple moving average is $35.90. The firm has a market capitalization of $2.42 billion, a P/E ratio of -2.40 and a beta of 4.46.

Analyst Ratings Changes

A number of analysts have recently weighed in on MAZE shares. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. HC Wainwright reiterated a “buy” rating on shares of Maze Therapeutics in a report on Wednesday, January 28th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $54.63.

Insider Buying and Selling at Maze Therapeutics

In other news, CMO Harold Bernstein sold 30,000 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $50.45, for a total transaction of $1,513,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Amy Bachrodt sold 5,000 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $46.04, for a total transaction of $230,200.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $596,908.60. The trade was a 27.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 230,000 shares of company stock valued at $9,768,292 in the last ninety days.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.